ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
February 22, 2024 08:30 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
January 30, 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
January 29, 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
January 08, 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of...
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
September 21, 2023 08:30 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced...
ProSomnus Announces Second Quarter 2023 Investor Call and Business Update
July 06, 2023 08:29 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its strong second...